{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:07:12Z","timestamp":1770484032634,"version":"3.49.0"},"reference-count":22,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12,1]]},"abstract":"<jats:title>This Policy Statement was retired January 2015.<\/jats:title>\n               <jats:p>The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention and the American Academy of Pediatrics approved updated recommendations for the use of quadravalent (serogroups A, C, W-135, and Y) meningococcal conjugate vaccines (Menactra [Sanofi Pasteur, Swiftwater, PA] and Menveo [Novartis, Basel, Switzerland]) in adolescents and in people at persistent high risk of meningococcal disease. The recommendations supplement previous Advisory Committee on Immunization Practices and American Academy of Pediatrics recommendations for meningococcal vaccinations. Data were reviewed pertaining to immunogenicity in high-risk groups, bactericidal antibody persistence after immunization, current epidemiology of meningococcal disease, meningococcal conjugate vaccine effectiveness, and cost-effectiveness of different strategies for vaccination of adolescents. This review prompted the following recommendations: (1) adolescents should be routinely immunized at 11 through 12 years of age and given a booster dose at 16 years of age; (2) adolescents who received their first dose at age 13 through 15 years should receive a booster at age 16 through 18 years or up to 5 years after their first dose; (3) adolescents who receive their first dose of meningococcal conjugate vaccine at or after 16 years of age do not need a booster dose; (4) a 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5\u2013C9, properdin, factor H, or factor D) deficiency (9 months through 54 years of age) or functional or anatomic asplenia (2\u201354 years of age) and for adolescents with HIV infection; and (5) a booster dose should be given 3 years after the primary series if the primary 2-dose series was given from 2 through 6 years of age and every 5 years for persons whose 2-dose primary series or booster dose was given at 7 years of age or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5\u2013C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia.<\/jats:p>","DOI":"10.1542\/peds.2011-2380","type":"journal-article","created":{"date-parts":[[2011,11,29]],"date-time":"2011-11-29T05:19:04Z","timestamp":1322543944000},"page":"1213-1218","source":"Crossref","is-referenced-by-count":32,"title":["Meningococcal Conjugate Vaccines Policy Update: Booster Dose Recommendations"],"prefix":"10.1542","volume":"128","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2011,12,1]]},"reference":[{"issue":"3","key":"2023092514504891200_B1","first-page":"72","article-title":"Updated recommendations for use of meningococcal conjugate vaccines: Advisory Committee on Immunization Practices (ACIP), 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"RR-7","key":"2023092514504891200_B2","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"54","author":"Bilukha","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"37","key":"2023092514504891200_B3","first-page":"1042","article-title":"Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"2023092514504891200_B4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1542\/peds.2005-1314","article-title":"Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patients","volume":"116","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2005","journal-title":"Pediatrics"},{"issue":"6","key":"2023092514504891200_B5","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1542\/peds.106.6.1500","article-title":"Meningococcal disease prevention and control strategies for practice-based physicians (addendum: recommendations for college students)","volume":"106","author":"American Academy of Pediatrics, Committee on Infectious Diseases","year":"2000","journal-title":"Pediatrics"},{"issue":"3","key":"2023092514504891200_B6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1542\/peds.97.3.404","article-title":"Meningococcal disease prevention and control strategies for practice-based physicians","volume":"97","author":"American Academy of Pediatrics, Committee on Infectious Diseases; Canadian Paediatric Society, Infectious Diseases and Immunization Committee","year":"1996","journal-title":"Pediatrics"},{"issue":"6","key":"2023092514504891200_B7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1086\/500512","article-title":"Antibody persistence 3 years after immunization of adolescents with quadrivalent meningococcal conjugate vaccine","volume":"193","author":"Vu","year":"2006","journal-title":"J Infect Dis"},{"issue":"11","key":"2023092514504891200_B8","doi-asserted-by":"crossref","first-page":"881","DOI":"10.4161\/hv.6.11.12849","article-title":"Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo) or Menactra among healthy adolescents","volume":"6","author":"Gill","year":"2010","journal-title":"Hum Vaccin"},{"issue":"11","key":"2023092514504891200_B9","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1086\/508776","article-title":"Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization","volume":"43","author":"Snape","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2023092514504891200_B10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1086\/652765","article-title":"Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999\u20132000 and response to a booster: a phase 4 clinical trial","volume":"50","author":"Perrett","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2023092514504891200_B11","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.inf.0000151029.58752.27","article-title":"Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine","volume":"24","author":"Snape","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"2023092514504891200_B12","author":"Cohn"},{"issue":"6","key":"2023092514504891200_B13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/INF.0b013e31820a8b3c","article-title":"Early estimate of the effectiveness of quadravalent meningococcal vaccine","volume":"30","author":"Macneil","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2023092514504891200_B14","author":"Cohn"},{"issue":"12","key":"2023092514504891200_B15","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1086\/509619","article-title":"Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom","volume":"194","author":"Auckland","year":"2006","journal-title":"J Infect Dis"},{"issue":"2","key":"2023092514504891200_B16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/0009922810379907","article-title":"Patient-provider communication and human papillomavirus vaccine acceptance","volume":"50","author":"Rand","year":"2011","journal-title":"Clin Pediatr (Phila)"},{"key":"2023092514504891200_B17","unstructured":"Ortega-Sanchez\u2008I\n          . Cost-effectiveness of Meningococcal Vaccination Strategies for Adolescents in the United States. Atlanta, GA: Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention; 2010. Available at: www.cdc.gov\/vaccines\/recs\/acip\/downloads\/mtg-slides-oct10\/02-3-mening-CostEffect.pdf. Accessed March 29, 2011"},{"issue":"27\u201330","key":"2023092514504891200_B18","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","article-title":"Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine","volume":"21","author":"Platonov","year":"2003","journal-title":"Vaccine"},{"issue":"3","key":"2023092514504891200_B19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1046\/j.1365-2249.1998.00738.x","article-title":"Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine","volume":"114","author":"Fijen","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"2023092514504891200_B20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","article-title":"Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals","volume":"72","author":"Balmer","year":"2004","journal-title":"Infect Immun"},{"issue":"5","key":"2023092514504891200_B21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/INF.0b013e3181c38f3b","article-title":"Phase I\/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoids conjugate vaccine in human immunodeficiency virus-infected adolescents","volume":"29","author":"Siberry","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"50","key":"2023092514504891200_B22","doi-asserted-by":"crossref","first-page":"7865","DOI":"10.1016\/j.vaccine.2010.09.092","article-title":"Comparison of the safety immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2\u201310 years of age","volume":"28","author":"Halperin","year":"2010","journal-title":"Vaccine"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/6\/1213\/1531483\/zpe01211001213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/128\/6\/1213\/1531483\/zpe01211001213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:52:04Z","timestamp":1695653524000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/128\/6\/1213\/31186\/Meningococcal-Conjugate-Vaccines-Policy-Update"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,1]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2011,12,1]]},"published-print":{"date-parts":[[2011,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2011-2380","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,1]]}}}